8-K: Myriad Genetics Reaffirms 2023 Guidance and Outlines Growth Strategy at J.P. Morgan Healthcare Conference

Myriad Genetics reaffirmed its fiscal year 2023 revenue and non-GAAP guidance, projecting positive adjusted operating cash flow in Q4 2023, and provided preliminary Q4 2023 financial results.

Summary

• Myriad Genetics presented at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024.
• The company reaffirmed its fiscal year 2023 revenue and non-GAAP guidance previously provided on November 6, 2023.
• Myriad expects to achieve positive adjusted operating cash flow in the fourth quarter of 2023.
• Preliminary fourth quarter 2023 revenue is expected to be between $196 and $197 million.
• Diluted GAAP earnings per share are projected to be between ($0.35) and ($0.36).
• Adjusted earnings per share are expected to be between $0.02 and $0.03.
• Both GAAP and adjusted gross margin are expected to be approximately 70%.
• The company anticipates revenue growth of at least 10% year-over-year for fiscal year 2023.
• Prenatal volume growth in the fourth quarter of 2023 is expected to be at least 10% year-over-year.
• Myriad estimates total available cash and credit at year-end 2023 to be $162.6 million.
• The company is targeting total revenue of over $1 billion in 2026.
• Myriad is targeting adjusted operating income of approximately $100 million in 2026, or 10% of total revenue.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with reaffirmed guidance, expected positive cash flow, and growth targets. However, it also acknowledges risks and uncertainties, leading to a moderately positive sentiment.

Positives

• The company reaffirmed its 2023 financial guidance, indicating confidence in its performance.
• Myriad is on track to achieve positive adjusted operating cash flow in Q4 2023, a significant milestone.
• The company expects strong revenue growth of at least 10% for fiscal year 2023.
• Myriad has a diversified portfolio within large, actionable markets.
• The company has a strong focus on innovation with multiple new tests expected to launch through 2026.
• Myriad has a strong commercial execution driving volume growth and price stability.
• The company has a healthy balance sheet and is increasing financial flexibility.
• Myriad is well positioned to take advantage of future market opportunities.

Negatives

• The preliminary financial data is based on unaudited internal reports and may change.
• The company is still finalizing its financial results for the quarter and full year ended December 31, 2023.
• The company faces risks related to competition, reimbursement, and regulatory requirements.
• There are risks related to the company's ability to secure additional financing if needed.

Risks

• Sales and profit margins of existing tests may decline.
• The company may not be able to operate its business on a profitable basis.
• There are risks related to achieving revenue growth targets and generating sufficient revenue from new products.
• Changes in governmental or private insurer coverage and reimbursement levels could impact the company.
• Increased competition and the development of new competing tests pose a risk.
• The company may be unable to develop or achieve commercial success for additional tests in a timely manner.
• There are risks related to delays or problems with constructing and operating laboratory testing facilities.
• The company faces risks related to security breaches, loss of data, and cyberattacks.
• Myriad may be unable to comply with financial operating covenants under its credit agreements.
• The company faces risks related to current and future investigations, claims, or lawsuits.

Future Outlook

Myriad Genetics expects to achieve positive adjusted operating cash flow in Q4 2023, anticipates 10%+ revenue growth in 2024 through 2026, and is targeting over $1 billion in revenue and $100 million in adjusted operating income by 2026. The company plans to launch multiple new tests in prenatal and oncology through 2026.

Management Comments

• Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors.
• Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business.

Industry Context

Myriad Genetics operates in the competitive genetic testing and precision medicine industry, facing competition from other diagnostic companies. The company is focusing on expanding its product portfolio and market reach in key areas such as oncology, women's health, and pharmacogenomics. The company is also investing in technology and infrastructure to improve efficiency and reduce costs.

Comparison to Industry Standards

• Myriad Genetics is a leader in genetic testing with established franchises in hereditary cancer, pharmacogenomics, and prenatal testing, similar to companies like Invitae and Exact Sciences.
• The company's focus on innovation and new product launches is consistent with industry trends, where companies are continuously developing new tests and technologies.
• Myriad's market penetration varies across different product categories, with some areas having higher penetration than others, similar to other companies in the space.
• The company's gross margins are in line with industry standards for genetic testing companies.
• Myriad's focus on operational efficiency and cost reduction is a common theme among companies in the diagnostics industry.

Stakeholder Impact

• Shareholders can expect continued growth and profitability improvements.
• Healthcare providers will have access to new and improved genetic testing options.
• Patients will benefit from more accurate and timely diagnostic information.
• Employees can expect a stable and growing work environment.

Next Steps

• The company plans to launch multiple differentiated tests in prenatal and oncology through 2026.
• Myriad will continue to invest in enterprise infrastructure and capability investments.
• The company will continue to expand its exome capability to undergird MyRisk, Foresight, Precise, and other products.
• Myriad will continue to accelerate the pace of EMR integrations through EMR providers.

Key Dates

Keywords

genetic testing, precision medicine, oncology, womens health, pharmacogenomics, prenatal testing, revenue growth, adjusted operating cash flow, financial guidance, MyRisk, GeneSight, Prolaris, Prequel, Foresight